I. Clinical Aspects and Investigations

Abstract
The use of radioactive yttrium (90Y) is reviewed as an alternative to 198Au for malignant effusions. Fifteen cases were treated by intracavitary injection of a new compound, colloidal yttrium silicate. Of nine patients surviving longer than one month, six received good palliation for periods ranging from five to 19 months. The intracavitary retention and extracavitary dosage are detailed and compared with those of other yttrium preparations and with gold.